Barrett’s esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies

Table 2 Efficacy of surgery for Barrett’s esophagus with submucosal adenocarcinoma

Ref.	Type	n	LNM rate	5-yr DFS	5-yr OS
Rice et al[97]	Retrospective	31	5%	-	60%
Liu et al[61]	Retrospective	37	-	60%	58%
Pennathur et al[59]	Retrospective	71	27%	62%	60%
Sepesi et al[72]	Retrospective	29	31%	-	60%
Hölscher et al[56]	Retrospective	101; SCC 35%	34%	-	66%
Leers et al[55]	Retrospective	51	22%	79%DSS	71%
Ngamruengphong et al[120]	Retrospective	523	-	-	64%
Lorenz et al[57]	Retrospective	168	20.6%	85%	74%
Schölvinck et al[78]	Retrospective	26	17% (n = 69 including EET group)	-	Median survival: 51 mo
Schwameis et al[76]	Retrospective	32	22%	-	84%
Newton et al[54]	Retrospective (NCDB)	512	23.4%	-	64.4%
Semenkovich et al[74]	Retrospective (NCDB)	1146; SCC 16%	14%	-	60%
Otaki et al[77]	Retrospective	68	14.7%	92%	89%

DSS: Disease specific survival; EET: Endoscopic eradication therapy; NCDB: National cancer database; DFS: Disease free survival; OS: Overall survival; SCC: Squamous cell carcinoma.